Novavax (NVAX) Stock Runs Up On New Data Presentation

Novavax NVAX Stock News

Novavax, Inc. (NASDAQ: NVAX) is having a great start to the trading session this morning, trading on gains of more than 7% early on. The gains come after the company presented new data from its Phase 3 Prepare trial. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

NVAX Stock Heads Up After New Data Is Presented

In a press release issued in the pre-market hours this morning, Novavax said that it presented new data from its Prepare trial. Prepare is a Phase 3 clinical trial of ResVax, the company’s RSV-F vaccine.

In the release, NVAX said that the presentation was provided by Dr. Getta K. Swamy, Associate Professor of Obstetrics and Gynecology and Vice Dean and Associate Provost for Scientific Integrity at Duke University. The presentation was held at the 2019 IDSOG Annual Meeting.

The Data

The data that was presented came from a recently completed analysis of one-year safety data. The data proved to be positive. In fact, it showed a 59.6% reduction in the incidence of serious adverse evensed diagnosed as pneumonia, which was confirmed via chest x-ray.  This effect lasted throughout the first year of life.

NVAX also said that the study demonstrated that efficacy of around 50% was seen for all SAEs with clinical diagnosis of pneumonia over the course of a year.

Once taking into account x-ray-confirmed pneumonia SAEs associated with the detection of RSV, efficacy climbed to 72.9% through the first 180 days o flife.

In a statement, Dr. Louis F. Fries III, CMO at NVAX, had the following to offer:

Ongoing analysis of the Prepare trial data is teaching us more about how and where the vaccine was most efficacious in reducing RSV infections and its most severe complications. Based on the incidence rate for clinical pneumonia SAEs in placebo subjects in the Prepare trial and the vaccine’s efficacy in reducing this rate, ResVax could have a public health impact, in terms of vaccine-preventable disease incidence or number of women needed to vaccinate to prevent one case of infant pneumonia, that is similar or in excess of pneumococcal conjugate vaccines for similar outcomes. Such insights are valuable as we explore potential regulatory and clinical development paths forward to deliver an effective vaccine to address a serious global unmet need.

The News Is Incredible

This news is incredible. Not just for parents worried about RSV-F in their newborns, but for Novavax and its investors.

The truth of the matter is that the RSV-F market is a massive one. In fact, experts expect that the market will grow to be worth well over $2 billion annually by the year 2024.

While it would be unreasonable to epect that NVAX or any other company would take 100% of this market, the company doesn’t need to. Considering the fact that the market cap at NVAX is sub-$100 million, even tapping into a very small percentage of this market could lead to serious return of value for investors.

Final Thoughts

At the end of the day, as NVAX continues to progress ResVax through development, data is positive, suggesting that approval may be around the corner. Of course, an approval would be a game changer for the company.

Moreover, it’s also worth mentioning that ResVax isn’t the only candidate here. In fact, I’ve been watching NanoFlu, the company’s influenza vaccine, incredibly closely and there’s a lot of promise there as well.

All in all, with positive data hitting the tape and multiple assets that have the potential to become blockbuster vaccines, NVAX is a stock that should not be ignored!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our mailing list below to receive free real-time alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.